Press Releases April 23, 2026 01:55 PM

Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report

Progyny announces date and details for Q1 2026 earnings report and conference call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
PGNY

Progyny, Inc., a leading women's health and family building solutions company, announced it will report its Q1 2026 financial results after market close on May 7, 2026, followed by a conference call. The press release details access information for investors and media, highlighting the company's market recognition and commitment to innovative health solutions.

Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
PGNY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Progyny will release Q1 2026 financial results on May 7, 2026, with an investor conference call scheduled.
  • The company is recognized as a leader in women's health, offering concierge support and advanced fertility solutions targeting employers and health plans.
  • Progyny has received numerous accolades including TIME100 Most Influential Company and CNBC Disruptor 50, signaling strong market presence and growth potential.

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.

An audio replay of the call will be available through Thursday, May 14, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.

A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.

For Further Information, Please Contact:

Investors:
James Hart
[email protected]

Media:
Alexis Ford
[email protected]


Risks

  • Financial results may not meet investor expectations, leading to stock volatility.
  • The fertility and women's health sector faces regulatory changes and reimbursement challenges affecting revenue.
  • Competition in the healthcare benefits market could impact Progyny's ability to maintain or grow its client base.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026